Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.

Against the odds GSK’s Dreamm-7 study yields a positive survival readout.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.

But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.

A prostate cancer project licensed from Orion enters phase 3, while pivotal trials are expanded with assets originated at Kelun and Arqule.

New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.